These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

58 related articles for article (PubMed ID: 9793878)

  • 1. In conclusion: does antipsychotic treatment modify the long-term course of schizophrenic illness?
    Tandon R
    J Psychiatr Res; 1998; 32(3-4):251-3. PubMed ID: 9793878
    [No Abstract]   [Full Text] [Related]  

  • 2. Impact of antipsychotic treatment on long-term course of schizophrenic illness: an introduction.
    Tandon R
    J Psychiatr Res; 1998; 32(3-4):119-20. PubMed ID: 9793864
    [No Abstract]   [Full Text] [Related]  

  • 3. Improving outcomes for patients with schizophrenia: new hope for an old illness.
    Seeman MV
    CMAJ; 1999 Mar; 160(6):826-8. PubMed ID: 10189430
    [No Abstract]   [Full Text] [Related]  

  • 4. Short and long term effects of antipsychotic medication on smooth pursuit eye tracking in schizophrenia.
    Hutton SB; Crawford TJ; Gibbins H; Cuthbert I; Barnes TR; Kennard C; Joyce EM
    Psychopharmacology (Berl); 2001 Sep; 157(3):284-91. PubMed ID: 11605084
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Prevalence of diabetes mellitus in chronic schizophrenic inpatients in relation to long-term antipsychotic treatment.
    Cohen D; Dekker JJ; Peen J; Gispen-de Wied CC
    Eur Neuropsychopharmacol; 2006 Apr; 16(3):187-94. PubMed ID: 16263247
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Indications for long-term pharmacological treatment of schizophrenic syndromes.
    Perris C
    Pharmakopsychiatr Neuropsychopharmakol; 1976 Jul; 9(4):149-58. PubMed ID: 10585
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Pharmacotherapy of schizophrenic patients in a long-term catamnestic study.
    Papezová H
    Homeost Health Dis; 1991; 33(5-6):289. PubMed ID: 18265501
    [No Abstract]   [Full Text] [Related]  

  • 8. Improving outcome in schizophrenia: the case for early intervention.
    Malla AK; Norman RM; Voruganti LP
    CMAJ; 1999 Mar; 160(6):843-6. PubMed ID: 10189434
    [No Abstract]   [Full Text] [Related]  

  • 9. The case for long-acting antipsychotic agents in the post-CATIE era.
    Nasrallah HA
    Acta Psychiatr Scand; 2007 Apr; 115(4):260-7. PubMed ID: 17355516
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Long-term medication in schizophrenic psychoses].
    Gaebel W
    Fortschr Neurol Psychiatr; 2000 Apr; 68 Suppl 1():S26-31. PubMed ID: 10907610
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Subjective well-being under antipsychotic treatment and its meaning for compliance and course of disease].
    Naber D; Lambert M; Karow A
    Psychiatr Prax; 2004 Nov; 31 Suppl 2():S230-2. PubMed ID: 15586315
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Introduction. Ziprasidone in schizophrenia: from acute treatment to long-term management.
    Kane JM
    J Clin Psychiatry; 2003; 64 Suppl 19():3-5. PubMed ID: 14728083
    [No Abstract]   [Full Text] [Related]  

  • 13. Preventing clinical deterioration in the course of schizophrenia: the potential for neuroprotection.
    Lieberman JA; Malaspina D; Jarskog LF
    CNS Spectr; 2006 Apr; 11(4):suppl 1-13; quiz suppl 14-5. PubMed ID: 16641837
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Atypical antipsychotics in the managed care era.
    Loebel AD; Botts SR; Feldman BI
    Am J Manag Care; 1998 Jan; 4 Suppl():S37-50; quiz S51-2. PubMed ID: 10181074
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Maintaining symptom control: review of ziprasidone long-term efficacy data.
    Schooler NR
    J Clin Psychiatry; 2003; 64 Suppl 19():26-32. PubMed ID: 14728087
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Long term drug treatments of schizophrenia].
    des Lauriers A; Allilaire JF
    Rev Prat; 1980 Jan; 30(1):39-46. PubMed ID: 6103572
    [No Abstract]   [Full Text] [Related]  

  • 17. [Influences of second generation antipsychotics on the course of schizophrenia].
    Messer T
    Psychiatr Prax; 2004 Nov; 31 Suppl 1():S161-3. PubMed ID: 15570540
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Reply to comments on "Optimizing early prediction for antipsychotic response in schizophrenia".
    Chang YC; Lane HY
    J Clin Psychopharmacol; 2009 Aug; 29(4):391. PubMed ID: 19593183
    [No Abstract]   [Full Text] [Related]  

  • 19. Factors affecting outcome in schizophrenia and their relevance for psychopharmacological treatment.
    Altamura AC; Bobo WV; Meltzer HY
    Int Clin Psychopharmacol; 2007 Sep; 22(5):249-67. PubMed ID: 17690594
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Is depot formulation a long-term optimal treatment option?].
    Musch A
    Med Monatsschr Pharm; 2005 Nov; 28(11):414-6. PubMed ID: 16309031
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 3.